Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) took a rather sharp beating yesterday on word that it was going to have a secondary offering. We now have details on that offering and it comes to 7.5 million shares at a price of $10.75 per share. Keep in mind that he $10.98 close on Tuesday was down from $12.39 on Monday and the close last Thursday was $13.05.
The company has a broad and diverse pipeline with many key partners. All of the shares are being sold by Alnylam.
The underwriting group is larger than what we originally saw as well: J.P. Morgan Securities is acting as the sole book-running manager for the offering; co-managers were listed as Leerink Swann, Needham & Company, JMP Securities, Rodman & Renshaw, MLV & Co., and Chardan Capital Markets. These underwriters have an overallotment option of 1.125 million shares.
Alnylam shares are trading up marginally at $11.00 per share as the appearance of the worst seems to be over. This one took a pretty steep haircut even before the secondary was announced and this will allow it to further develop that extensive pipeline and partnerships.
JON C. OGG
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
